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Androgen-Dependent Neurodegeneration
by Polyglutamine-Expanded Human Androgen
Receptor in Drosophila
of the AR protein (La Spada et al., 1991; Choong and
Wilson, 1998; Merry and Fischbeck, 1998). These re-
peats encode polyglutamine (polyQ) stretches, and it
has been found that disease onset occurs when the
stretches contain more than 40 glutamine residues,
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compared to a range of 8 to 34 polyQ stretches in normal1Institute of Molecular and Cellular Biosciences
individuals. SBMA patients often suffer mild androgenUniversity of Tokyo
insensitivity, indicating impaired AR function due to the1-1-1 Yayoi, Bunkyo-ku
expanded polyQ stretches (Pinsky et al., 1992). How-Tokyo 113-0032
ever, it appears unlikely that motor neuronal cell death2 Institute for Drug Discovery Research
is caused simply by the loss of AR function, as neurode-Yamanouchi Pharmaceutical Co., Ltd.
generation is not observed in severe testicular feminiza-21 Miyukigaoka, Tukuba
tion (Tfm) patients that completely lack AR functionIbaraki 305-8585
(Brown et al., 1988; Yong et al., 1994). Like other neuro-3 Laboratory for Cell Recovery Mechanisms
degenerative diseases involving polyQ stretches, suchBrain Science Institute
as Huntington’s disease (HD), dentatorubral and pallido-RIKEN
luysian atrophy (DRPLA), and spinocerebellar ataxia at-2-1 Hirosawa, Wako
rophy (SCA), formation of mutant protein aggregatesSaitama 351-0198
is observed in SBMA patients with a loss of selected4 CREST
neuronal populations (Kim and Tanzi, 1998). AbnormalJapan Science and Technology
folding of polyglutamine-expanded proteins may cause4-1-8 Honcho, Kawaguchi
neural death through a common mechanism, as evi-Saitama 332-0012
denced by the production of aggregates in these dis-Japan
eases (Ross, 1997). While polyQ-expanded hAR protein
expressed in cultured cells has been shown to have
reduced transactivation function, ligand binding is indis-Summary
pensable for aggregate formation (Stenoien et al., 1999).
AR is a member of the nuclear receptor superfamilySpinal and bulbar muscular atrophy (SBMA) is an
and acts as a ligand-inducible factor to control transcrip-X-linked, adult-onset, neurodegenerative disorder af-
tion of a particular set of target genes (Mangelsdorf etfecting only males and is caused by expanded polyglu-
al., 1995; Glass and Rosenfeld, 2000). Members of thetamine (polyQ) stretches in the N-terminal A/B domain
steroid/thyroid hormone family share common struc-of human androgen receptor (hAR). Although no overt
tural features, with distinct functional domains, referredphenotype was detected in adult fly eye photoreceptor
to as domains A to E/F. The highly conserved middleneurons expressing mutant hAR (polyQ 52), ingestion
region (C domain) acts as a DNA binding domain (DBD),of androgen or its known antagonists caused marked
while the ligand binding domain (LBD) is located in theneurodegeneration with nuclear localization and struc-
less well-conserved C-terminal E/F domain. The LBDstural alteration of the hAR mutant. Ligand-independent
of most nuclear receptors, including AR, have been ana-toxicity was detected with a truncated polyQ-expanded
lyzed and are comprised of 12  helices that form aA/B domain alone, which was attenuated with cyto-
pocket to capture cognate ligands (Shiau et al., 1998;solic trapping by coexpression of the unliganded hAR
Poujol et al., 2000). Upon ligand binding, the C-terminal
E/F ligand binding domain. Thus, our findings sug-
 helix 12 (H12) in the LBD shifts position to create a
gest that the full binding of androgen to the polyQ- space, with helices 3 to 5 serving as the key interface
expanded hAR mutants leads to structural alteration following dissociation of corepressor complexes and
with nuclear translocation that eventually results in association of coactivator complexes (Freedman, 1999;
the onset of SBMA in male patients. Glass and Rosenfeld, 2000; Mckenna and O’Malley,
2002; Yanagisawa et al., 2002). During ligand-induced
Introduction transactivation, the two N-terminal domains A/B and the
steroid receptor LBD act as interacting regions for the
Spinal and bulbar muscular atrophy (SBMA), or Kenne- coactivator complexes (He et al., 1999; Watanabe et al.,
dy’s disease, is a rare degenerative disease of the motor 2001; Shang et al., 2002). The autonomous activation
neurons, characterized by progressive muscle atrophy function-1 (AF-1) within the A/B domain is ligand inde-
and weakness in male patients, usually beginning at pendent, while the AF-2 in the LBD is induced upon
30–50 years of age (Kennedy et al., 1968). Mapping stud- ligand binding (Kato et al., 1995). Unliganded LBD ap-
ies and functional analyses of SBMA cases revealed pears to suppress the function of AF-1, while ligand
expansions in the number of trinucleotide CAG repeats binding to the LBD is thought to evoke the function of
in the first exon of the androgen receptor (AR) gene, LBD and to restore the A/B domain function through an
generating expanded polyQ stretches in the A/B domain as yet undescribed intramolecular alteration of the entire
steroid receptor structure. As SBMA occurs in men
rather than women, we reasoned that a critical step in5 Correspondence: uskato@mail.ecc.u-tokyo.ac.jp
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Figure 1. Ligand-Induced Degeneration in Photoreceptor Neurons by hAR Mutants with Expanded PolyQ Stretches
(A) Diagram of the AR constructs. Location of the polyglutamine (polyQ) region (red boxes) in relation to the DNA binding domain (DBD) (black
boxes). Transactivation function 1 (AF-1) region is localized within the N-terminal A/B domain, and transactivation function 2 (AF-2) region is
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the onset of SBMA could be the structural alteration and Rubin, 1991), using the Drosophila melanogaster
GAL4-UAS system (Brand and Perrimon, 1993). Usingand nuclear translocation of mutant AR upon binding of
significant amounts of androgen. this system, targeted expression of hARs was also
achieved in the anterior portion of embryonic segmentsTo test this hypothesis, we investigated the role of
hAR mutants with expanded polyQ stretches in neuro- by a patched (ptc) gene promoter and to the anterior-
posterior boundary area in developing wing discs underdegeneration. To this end, we established a Drosophila
model that ectopically overexpressed a mutated AR in a decapentapregic (dpp) gene promoter (data not
shown) (Tanimoto et al., 2000). Northern blot analysisphotoreceptor neurons. Although the fly eye has proved
to be an effective model in which to observe neuronal from different tissues of DHT-treated and untreated
transgenic flies (data not shown) suggests that ectopicdegeneration through the expression of other mutant
proteins containing polyQ stretches (Jackson et al., expression of hAR did not affect the expression of
endogenous nuclear receptor genes (e.g., Eip75B,1998; Warrick et al., 1998), no abnormalities were found
in eyes expressing a mutant hAR that contained an ex- ecdysone receptor) (White et al., 1997). To monitor the
ligand-induced transactivation function of hAR, hAR-panded 52 stretch polyQ (Q52). However, dietary inges-
tion of dihydroxytestosterone (DHT) induced marked de- expressing flies were further crossed to fly lines bearing
a GFP reporter gene, such that GFP expression couldgeneration of the photoreceptor neurons, along with
apoptosis, although the mutant hAR still retained re- be induced by ligand-bound AR that recognized the
consensus androgen response element (ARE) in the GFPduced transactivation function. Neurodegeneration was
induced even in the absence of DHT when only the promoter (Yamamoto et al., 2000). Expressed hARs were
then detected as red fluorescence in situ using an immu-A/B domain, which harbors the 52 polyQ stretch, was
expressed but was abrogated by coexpression of unli- nofluorescent antibody. Dietary ingestion of androgen
(dihydrotestosterone/DHT) for 5 days from hatching in-ganded LBD domain. Surprisingly, known androgen
antagonists failed to suppress the DHT-induced neu- duced remarkable and targeted GFP expression ob-
served as green fluorescence in eye discs of third instarrodegeneration in the Q52 line. Trapping the polyQ-
expanded receptor mutants in the cytosol prevented larva by the GMR promoter (Figure 1B) and in the other
tissues by the ptc and dpp promoters (data not shown).neurodegeneration. Thus, our results suggest that hor-
mone binding and subsequent structural alteration of Two independent transactivation functions (AF-1 in the
A/B and AF-2 in the E/F domain of AR) were detectedhAR mutants with nuclear localization appears to be
critical for SBMA onset. Furthermore, they reveal that in eye discs (Figure 1B), as observed in cultured mam-
malian cells (Yamamoto et al., 2000; Ikonen et al., 1997).the fly eye model may be useful for the development of
novel therapeutic approaches to SBMA. These observations indicate that ectopic expression of
hARs translocated into the nuclei upon DHT binding and
activated transcription in the tissues examined.
Results
Targeted Expression of Functional Human Ligand-Induced Neurodegeneration in the Fly
Line Expressing Polyglutamine-ExpandedAndrogen Receptor in Drosophila
We investigated the role of hAR mutants that contain Human Androgen Receptor
We then characterized the expanded polyQ hAR mu-expanded polyQ stretches by ectopic expression in the
Drosophila eye (Figure 1A). The fly eye has proven to tants. The reduction in the hormone-induced transacti-
vation function of hAR mutants in COS-1 cells was de-be an effective model to observe neuronal degeneration
through the expression of other mutant proteins that pendent on the length of polyQ stretches in the A/B
domain (Figures 1A and 1C). An hAR mutant that con-also contain polyQ stretches (Jackson et al., 1998; War-
rick et al., 1998). We first expressed wild-type and mu- tained a 52 polyQ stretch [hAR(Q52)] exhibited only a
slight reduction in DHT-induced transactivation (Figuretated hARs (Figure 1A) in photoreceptor neurons and
accessory pigment cells in developing eye discs under 1C) but showed normal translation efficiency as esti-
mated by in vitro translation (Figure 1D), while expres-a glass multimer reporter (GMR) gene promoter (Moses
localized within the C-terminal E/F domain (gray boxes) containing the ligand binding domains (LBD). Nuclear export signals (NES) derived
from MEK (Toyoshima et al., 1998) were tagged at the N terminus.
(B) hAR mutant expression and transactivation function in eye discs. Expression of hAR(wt), hAR(Q52), hAR(AF-1), and hAR(AF-2) in third
instar eye imaginal discs driven by GMR-GAL4 was detected using anti-hAR N-20 and/or C-19 antibodies (left panel). Transactivation function
of hAR mutants was assessed using GFP expression (middle panel). A merged image is shown in the right panel.
(C) Reduction in the transactivation function of hAR mutants is dependent on polyQ length. COS-1 cells were cotransfected with 1 g ARE-
tk-luc and 0.1 g AR expression vector (wt, Q52, Q92, Q132, or Q212), and 108 M DHT was added to the medium 6 hr after transfection
(black boxes). After 18 hr, firefly luciferase activity (from ARE-tk) was measured to obtain the transfection efficiency, as previously described
for Renilla luciferase activity (from pRL-CMV) (Yamamoto et al., 2000).
(D) In vitro translated hARs. Wild-type and mutant hARs were produced by in vitro translation (TNT-coupled in vitro translation system,
Promega) in the presence of [35S]methionine. Labeled proteins were separated by SDS-PAGE and analyzed by autoradiography. No stable
protein can be produced for hAR(Q132) or (Q212).
(E) Rough-eye phenotype induced in hAR(Q52) lines by DHT or AR antagonists. Light microscopic (LM) and scanning electron microscopic
(SEM) images of adult eyes from 5-day-old flies treated as larval with or without 105 M DHT, HF, or BIC, respectively (closed arrow in Figure
2A). Genotypes are UAS-hAR(wt) or UAS-hAR(Q52) in trans to GMR-GAL4. While no degeneration is detectable after expression of the hAR(wt)
protein, severe degeneration was observed in hAR(Q52) lines after treatment with the ligands. Scale bar: whole eye, 100 m; eye inset, 10 m.
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Figure 2. Enhanced Neurodegeneration in Photoreceptor Neurons of hAR(Q52) Lines by Ligand Ingestion
(A) Experimental schedule for ligand treatment. The ligands were given for 5 days after hatching (closed arrow) or for 2 weeks to adult flies
after eclosion (opened arrow).
(B) Ligands induced neurodegeneration during adulthood. Genotypes are UAS-hAR (Q52) or UAS-Q127 in trans to GMR-GAL4. Adult transgenic
flies were kept for 2 weeks on medium containing vehicle or ligands (105 M DHT or HF). Scanning electron microscopic images (SEM) of
vertical (VS) and horizontal (HS) toluidine blue-stained sections show ligand-dependent degeneration in the hAR(Q52) line but not in the Q127
line. Eyes from six flies were analyzed for each genotype after 2 weeks with or without 105 M DHT or 105 M HF from eclosion. Degeneration
was also observed in two other independent transgenic lines.
(C) Genetic suppression of ligand-induced neurodegeneration in hAR(Q52) lines by the chaperone component Hsp40. Genotypes are GMR-
GAL4;UAS-hAR(Q52) in trans to UAS-dhdj-1(dhsp-40). The analysis of fly eyes in the presence of 105 M DHT by LM and SEM shows a
reduction of the pigmentation and rough-eye phenotype by expression of Hsp40 in fly eye.
(D) Expression of the hAR(wt) and hAR mutant proteins in transgenic fly eyes. The intact adult eyes of hAR (wt), hAR(Q52), or hAR(Q52 AF-1),
treated with or without DHT for 2 weeks, were dissected and analyzed by Western blotting using an N-terminal-specific anti-hAR antibody
(anti-hAR N20). Molecular weights (kDa) are indicated on the left.
sions of hAR(Q132) and hAR(Q212) proteins appeared cells (Figure 1C). We then tested whether androgen an-
tagonists could antagonize hAR(Q52) function and pre-at very low levels, judging from their translation effi-
ciency (Figure 1D). Transgenic fly lines that expressed vent eye disruption. As observed in other tissues, hydro-
xyflutamide (HF) and bicalutamide (BIC), as expected,hAR(Q52) in the eye under the GMR promoter showed
nearly normal eye morphology (Figures 1B and 1E) by depressed hAR(Q52) and hAR(wt) transactivation func-
tion but did not affect receptor protein expression levelslight microscopy (LM) and scanning electron micros-
copy (SEM) throughout the life span of the fly, and no in the fly eye discs (Figure 1B). Although the antagonists
potently blocked DHT-induced hAR transactivationother tissues examined appeared to be affected (data
not shown). However, we found that ingestion of DHT functions (data not shown), surprisingly, both antago-
nists not only failed to prevent but, indeed, appeared tofor 5 days after hatching (Figure 2A) induced marked
disruption of the eye, including severely reduced omma- potentiate eye disruption, leading to even more extreme
phenotypes with increased loss of red pigmentation withtidia numbers and loss of pigmentation with thinned
retinas in all lines tested at adult day 0 (see “DHT” treat- retinal degeneration as compared to that observed using
DHT alone (Figure 1E). The antagonists themselves ap-ment in right panels of Figure 1E). Notably, hAR(Q52)
expression levels in the eye discs appeared to be unaf- peared not to be toxic to the fly eye, as no phenotypic
abnormalities were induced in either developing or adultfected compared to those of hAR(wt), both with and
without DHT ingestion (Figure 1B). Despite the marked eyes in wild-type hAR lines (Figure 1E) or in any of the
tissues examined from normal flies (data not shown).neurodegeneration in the adult eyes, DHT-induced
transactivation function of hAR(Q52) in the eye disc nu- However, it remained unclear whether the rough-eye
phenotype induced by hAR ligand treatment at larvalclei was still detected (Figure 1B), as seen in COS-1
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stages was due to impaired eye formation during devel- sensitivity of the photoreceptor neurons to polyQ stretch,
as expected from previous reports that wild-type diseaseopment or to neuronal degeneration. To address this
issue, AR ligands were given to adult fly lines for 2 weeks proteins with normal polyQ stretches could cause neuro-
degeneration in the fly eyes (Fernandez-Funez et al., 2000).following eclosion (Figure 2A). DHT treatment in adults
led to severe rough-eye phenotypes in the hAR(Q52) Indeed, a shortening of the polyQ stretches to five repeats
in the A/B domain [hAR(Q5AF-1)] resulted in loss of toxic-lines in 14 day adults, with loss of photoreceptor neu-
rons, retina, and red pigmentation as observed by SEM ity (Figure 3A). However, we cannot exclude the possibil-
ity that the expressed hAR(Q52AF-1) and hAR(AF-1) pro-and LM with vertical and horizontal sections (VS and
HS) (left panels in Figure 2B), clearly indicating that the teins are in altered structures, which exhibit toxicity
more than those of full-length hARs. Notably, the coex-eye disruption induced by DHT reflects neurodegenera-
tion. The androgen antagonist HF also induced eye dis- pression of unliganded LBD domain [hAR(AF-2)] attenu-
ated the neurodegeneration induced by hAR (Q52AF-1)ruption in the hAR(Q52) lines (left panels in Figure 2B).
The rough-eye phenotype we observed looked similar (Figure 3C), presumably by trapping the hAR(Q52AF-1)
in the cytosol. However, DHT treatment aborted thisto that of flies expressing other polyQ mutant proteins
(Jackson et al., 1998; Warrick et al., 1998). As expected, attenuation (Figure 3C). These results indicated that unli-
ganded LBD domain masks the toxic effects of the polyQneurodegeneration was induced by expressing a frag-
ment with 127 polyQ (right panels in Figure 2B) (Kazemi- stretches as well as their transactivation function in the
A/B domains. However, upon ligand binding, the toxicEsfarjani and Benzer, 2000). However, no ligand treat-
ments potentiated the rough-eye phenotype (Figure 2B), and transactivation functions of the polyQ-expanded A/B
domain may be restored, accompanied with transloca-suggesting that the AR ligands themselves were not
enhancing polyQ-induced degeneration. Furthermore, tion into the nuclei.
We further tested whether nuclear localization is nec-the DHT effect was blocked by coexpression of Hsp40
(dhdj-1), a common suppressor of neurodegeneration by essary for the expression of the toxicity by the expanded
polyQ stretches in the hAR A/B domain by hAR mutantspolyQ-expanded proteins (Figure 2C) (Kazemi-Esfarjani
and Benzer, 2000; Warrick et al., 1999). The DHT treat- with a nuclear export signal (NES) (Toyoshima et al.,
1998) (see Figure 1A), which is expected to constitutivelyment did not appear to affect the expression levels of
hAR(Q52) or hAR(wt) as observed by Western blotting retain the cognate protein in the cytosol. The addition
of an NES to hAR(AF-1) lacking the D domain harboringwith an antibody against the N-terminal end of hAR (Fig-
ure 2D). Most notably, an N-terminal fragment con- the nuclear localization signal (NLS) (Zhou et al., 1994)
[hAR-NESNLS (Q52 AF-1)] resulted in a predominanttaining the expanded polyQ repeats was generated in
a DHT-dependent manner in the adult eyes of the localization in the cytosol, and the DHT-induced nuclear
localization of hAR(Q52) was prevented by the tagged-hAR(Q52) line (Figure 2D). No eye disruption was in-
duced in the adult hAR(wt) lines by the hAR ligand treat- NES [hAR-NES(Q52)] (Figure 3B). In agreement with their
cytosolic localization and lack of GFP induction by trans-ment (data not shown). Thus, the function of hAR(Q52)
in the induction of the rough-eye phenotype, which is activation functions of hARs (Figure 3B), the mutants
tagged with the NES exerted no toxicity in the fly eyesinduced by ligand binding, cannot distinguish between
DHT and androgen antagonists. Again, the features of (Figure 3D), clearly establishing that nuclear localization
is a prerequisite for the onset of neurodegeneration byDHT-dependent neurodegeneration in hAR(Q52) lines
appeared to strongly resemble the neural abnormalities the hAR mutants.
in the male SBMA patients, and it would be interesting to
compare the effect of anti-androgen treatment in these Ligand Binding Induces Toxicity
patients. However, no such clinical data are available. of the PolyQ-Expanded hAR
A/B Domain with Structural Alteration
We then directly analyzed androgen-induced alterationsNuclear Localization Is Necessary for Expression
of the Toxicity by the PolyQ-Expanded in hAR structure using a GST pull-down assay. While
androgen-dependent interactions between the A/B andhAR A/B Domain
To explore the molecular mechanism of androgen de- E/F domains were observed for hAR(wt) (Figure 4A, lane
3), hAR(Q52) exhibited ligand-dependent dissociationpendency of hAR(Q52)-induced neurodegeneration, we
first examined the effect of a truncated polyQ-expanded (Figure 4A, lane 5). This indicated that structural alter-
ations took place upon ligand binding for both wild-typeA/B domain construct, hAR(Q52AF-1) (Figure 1A). A chi-
meric hAR(Q52AF-1) protein fused only to the nuclear hAR and hAR(Q52), irrespective of the distinct structures
of unliganded hAR(Q52) compared to hAR(wt). The li-localization signal (NLS) of hAR was sufficient to induce
marked toxicity (Figure 3A) with relevant expression lev- gand-induced alterations in receptor structure were fur-
ther visualized using a trypsin digestion assay. Again,els to those of hAR(Q52) (Figure 2D), along with AF-1
transactivation function, even in the absence of ligand it was evident from the digestion patterns that structural
alterations induced by DHT binding for hAR(wt) and(right panels in Figure 1B). hAR(Q52AF-1) protein was
predominantly localized to the nucleus, in agreement hAR(Q52) were not identical (Figure 4B), in agreement
with the observations in the adult eyes of hAR(Q52) lineswith a ligand-independent and constitutive transactiva-
tion function (Figure 3B), while nuclear localization of that DHT treatment induced the generation of a fragment
containing the polyQ repeats (Figure 2D). Thus, thesehAR(Q52) was observed only in the presence of a ligand
(Figure 3B). The wild-type A/B domain [hAR(AF-1)] alone results suggest that structural alterations of hAR mu-
tants by ligand binding rendered the polyQ-expandedexhibited slight toxicity due to the wild-type 21 polyQ
stretches (Figure 3A), presumably together with more A/B domain more accessible to proteolysis, resulting in
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Figure 3. PolyQ-Expanded hAR AF-1 Alone Is Sufficient to Cause Neurodegeneration
(A) Ligand-independent neurodegeneration by hAR (Q52 AF-1). Genotypes are UAS-hAR (AF-1), UAS-hAR (Q52 AF-1), UAS-hAR (Q5 AF-1),
or UAS-hAR (AF-2) in trans to GMR -GAL4. Transgenic flies were kept on medium containing vehicle or ligands (105 M DHT or HF). While
hAR(AF-1) and hAR(Q52 AF-1) induced degeneration even without ligand treatment, expression of hAR(Q5 AF-1) did not induce detectable
degeneration, even after the treatment of ligands.
(B) Localization of hAR mutants in the third instar eye imaginal discs. hAR(AF-1) and (Q52 AF-1) predominantly localized to nuclei irrespective
of DHT ingestion, but the nuclear localization of hAR(wt) and hAR(Q52) required DHT. Expression of hAR(wt), hAR(Q52), hAR(AF-1), hAR(Q52
AF-1), hAR-NESNLS(Q52 AF-1), and hAR-NES(Q52) in third instar eye imaginal discs driven by GMR -GAL4 were detected using anti-hAR
N-20 (left panel), and chromosomal DNA was stained with propidium lodide (PI), transactivation function of hAR mutants assessed using GFP
expression (GFP), and merged image are shown in the right panel.
(C) Attenuation of hAR(Q52 AF-1)-induced neurodegeneration by unliganded hAR(AF-2). Genotypes are GMR-GAL4;UAS-hAR(Q52 AF-1) in
trans to UAS-hAR(AF-2). Without DHT, the expression of hAR(AF-2) suppressed the degeneration induced by hAR(Q52 AF-1). Treatment with
DHT (105 M) abolished this effect.
(D) No toxicity of hAR mutants in the cytosol. Genotypes are GMR-GAL4;UAS-hAR NESNLS(Q52 AF-1) or UAS-hAR NES(Q52). Transgenic
flies were kept on medium containing vehicle or ligands (DHT 105 M). The addition of a nuclear export signal to hAR(Q52 AF-1) or (Q52)
abolished the toxic effect.
the generation of fragments that could potentially be activation function of EcR is completely dependent upon
toxic. ligand binding. Specific DNA elements that bind EcR
and other fly nuclear receptor molecules are thought to
be composed of a directly repeated 5-AGGTCA-3 coreDiscussion
motif (DRs), whereas vertebrate steroid hormone recep-
tor homodimers bind a pair of core motifs arrangedThe Transactivation Function of hAR Expressed
as inverted core motifs (IRs). The opposite orientationin Drosophila Is Maintained without Affecting
between DRs and IRs is thought to render ectopic ex-the Endogenous Nuclear Receptor System
pression of vertebrate steroid receptors in DrosophilaDrosophila melanogaster possesses a number of en-
unable to compete with endogenous fly receptors indogenous nuclear receptors that are functionally homol-
DNA binding. However, as there are functional similari-ogous to members of the vertebrate nuclear receptor
ties in gene regulation between vertebrate and insectsuperfamily (White et al., 1997). Of the fly nuclear recep-
nuclear receptors, it is speculated that there may be ators, the physiological role of the ecdysone receptor
common coregulatory system that supports the trans-(EcR) has been well-documented (Bender et al., 1997).
Like vertebrate steroid hormone receptors, the trans- activation function of nuclear receptors. Indeed, two
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Figure 4. Structural Alteration Induced by Li-
gand Binding Differs between Wild-Type and
Mutant hARs
(A) Ligand-induced dissociation of hAR(AF-2)
and hAR(Q52 AF-1) in vitro. Interaction was
assessed by incubating a GST fusion protein
with either hAR(AF-1) [GST-AR(AF-1)], mutant
hAR(AF-1) with Q52 [GST-AR(Q52 AF-1)], or
GST-hTIF2 as a positive control, with in vitro
translated [35S]methionine-labeled hAR LBD
by pcDNA3-hAR 560-919. A ligand-induced
interaction between hAR LBD [hAR(AF-2)]
and hAR A/B domain [hAR(AF-1)] was ob-
served, while a ligand-depedent dissociation
is seen for the hAR A/B domain mutant
hAR(Q52 AF-1).
(B) Different structural alterations of hAR(wt)
and hAR(Q52) induced by ligand binding. In
vitro translated hAR(wt) and hAR(Q52) were
incubated with or without DHT or HF (105 M)
and were digested with 0, 5, or 10 ng of tryp-
sin for 10 min at 32C with (right panel) or
without (left panel) recombinant hAR LBD ex-
pressed in E. coli. Two hAR (Q52)-specific
fragments (arrow bands) can be detected by
autoradiography after ligand treatment and
digestion.
homologs to mammalian nuclear receptor coactivators that extensively analyzed common events in those
transgenic fly lines suggested that aggregate formationCBP and AIB1 have been recently identified in Drosoph-
ila (Akimaru et al., 1997; Bai et al., 2000). may cause neurodegeneration, which also appears to
occur in Q52 lines. These neurodegenerate events areEctopic expression of hAR targeted to particular tis-
sues by specific promoters appeared functional in li- thought to be mediated through factors associated with
the expanded polyQ stretches in the aggregates andgand-induced transactivation in all tissues tested, in-
cluding the eye. Both unliganded and liganded hAR(wt) not through any innate function of the disease proteins.
This hypothesis is further supported by the fact that nowere nontoxic in the transgenic flies under all conditions
studied, such that no phenotypic abnormalities were phenotypic abnormalities in the fly eye expressing wild-
type hAR were observed, even in the presence of ligand.observed in any of the tissues. Also, the activities of
ingested AR ligands agreed well with results obtained Thus, ligand-induced neurodegeneration caused by AR
mutants is most likely directly due to the expanded polyQusing mammalian cultured cells and intact mammals.
Thus, it is clear that the fly system will be a useful tool stretches in the hAR A/B domain and not to indirect
alterations in hAR function.in helping to dissect the function of vertebrate steroid
hormone nuclear receptors and for the genetic screen-
ing of coregulators and chromatin remodeling factors Onset of Neurodegeneration by hAR Mutants
Is Hormone Dependentthat are essential for the ligand-induced transactivation
function of steroid receptors. The androgen receptor is one of several neurodegenera-
tive disease proteins which harbors an expanded polyQ
stretch. However, in sharp contrast to other neurode-Polyglutamine-Expanded Human Androgen
Receptor Induces Degeneration generative disease-associated mutant proteins, SBMA
develops only in men (Kennedy et al., 1968; Choong andof Photoreceptor Neurons
Ligand binding induces the transactivation function of Wilson, 1998). In the present study, we clearly show in
an intact animal model that the onset of neurodegenera-AR, including the structural alteration required to acti-
vate the transcription of target genes via direct binding tion is completely dependent on androgen binding to
mutant hAR and nuclear translocation. Moreover, theto specific DNA promoter elements (Freedman, 1999;
Poujol, et al., 2000). However, it is unlikely that the li- mutated hAR A/B domain (Q52 AF-1) alone, when trans-
ported into nuclei, was sufficient to promote androgen-gand-induced neurodegeneration caused by polyQ-
expanded AR mutants is directly related to the binding independent toxicity as well as transactivation, whereas
coexpression of unliganded LBD abrogated the neuro-of mutant AR to the promoters of genes involved in
neuronal cell death. First, the androgen antagonists did degeneration induced by the A/B domain mutant, pre-
sumably by trapping the A/B domain in the cytosol.not induce transactivation function of the human AR
mutants (Figure 1B) but induced neurodegeneration Although the structures of unliganded and liganded hAR
mutants are likely to differ from androgen-bound wild-(Figure 2B). Second, the features of late-onset neurode-
generation in the eyes of Q52 transgenic fly lines ap- type hAR, polyQ-expanded hAR A/B domains appeared
to be functionally exposed, like the wild-type hAR A/Bpeared indistinguishable from transgenic flies express-
ing other polyQ-expanded disease proteins (Warrick et domain, only upon androgen binding (Yamamoto et al.,
2000; Ross, 1997; Watanabe et al., 2001). These findingsal., 1998; Jackson et al., 1998). Third, previous studies
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strongly indicate that the polyQ-expanded AR A/B do- molecular basis by which structural alterations caused
by agonist or antagonist binding modulate AF-2. In con-mains in the SBMA patients are functionally and physi-
cally masked by the unliganded ligand binding domain in trast, due to technical limitations of structurally analyz-
ing the whole nuclear receptor, little is known of thethe cytosol. Androgen binding to mutant hARs induced
structural alterations and translocation into the nuclei structural basis of A/B domain structural alteration upon
ligand binding and subsequent AF-1 induction. How-that resulted in toxicity. Thus, together with the fact that
serum androgen levels in adult men are 10 to 20 times ever, it is evident that an intramolecular structural alter-
ation involving the entire receptor molecule takes placehigher than in women, the androgen-dependent onset
of the neurodegeneration in the fly eye may explain why after ligand binding that exposes the A/B domain and
allows AF-1 activation (Kato et al., 1995; Watanabe etonly men suffer SBMA.
al., 2001; Kitagawa, et al., 2002). The A/B domain may
be exposed upon ligand binding, such that coactivatorNuclear Localization of PolyQ-Expanded hAR
complexes are recruited after dissociating from the li-Mutants Depends on Ligand Binding
gand-bound LBD domain. Alternatively, it is also possi-The nuclear localization of hAR mutants, like huntingtin
ble that coactivator complexes recruited to the LBDand spinocerebellar ataxia type 1 (SCA1) mutants (Kle-
upon ligand binding form a bridge to the A/B domainment et al., 1998; Saudou et al., 1998), appears to be
by releasing an inhibitory factor that suppresses AF-1.critical for the onset of neurodegeneration, since the
While mutated hAR A/B domains appear to be func-toxicity of the hAR mutants was abolished when the
tionally exposed upon ligand binding, the resultantpolyQ-expanded hAR mutants were trapped in the cyto-
structural alterations in hAR mutants are likely to differsol by tagged-NES, even in the presence of ligand (Fig-
from those of ligand-bound wild-type hAR. While knownures 3C and 3D). Moreover, the polyQ-expanded A/B
androgen antagonists are capable of inactivating thedomain mutant [hAR(Q52AF-1)], which constitutively lo-
transactivation function of mutant hAR structures, thecalizes in the nuclei (Figure 3B) with the autonomous
structurally altered mutant hAR still appears to be in atransactivation function (Figure 1B), caused ligand-inde-
position to exhibit the toxicity. Judging from expressionpendent neurodegeneration (Figure 3A). Nevertheless,
levels in fly eyes treated with and without DHT, it isthe neurodegeneration induced by hAR(Q52AF-1) was
unlikely that the half-life of the hAR(Q52) protein is signif-attenuated by coexpression of the unliganded LBD E/F
icantly affected by ligand binding. It has been previouslydomain [hAR(AF-2)] (Figure 3C), which appears to trap
demonstrated that some mutant polyQ proteins are al-the A/B domain mutant in the cytosol. More interestingly,
ternatively cleaved by proteases (Merry et al., 1998;known androgen antagonists clinically applied in andro-
Stenoien et al., 1999). It has been suggested that thesegen-dependent prostate cancer (Ruijter et al., 1999)
truncated proteins are toxic (Ross, 1997; Kim and Tanzi,failed to attenuate the DHT-induced neurodegeneration
1998). We find that ligand binding of the mutant hARin the hAR(Q52) line. Although these antagonists were
receptor results in the generation of an N-terminal frag-effective in blocking transactivation function of hAR mu-
ment (see Figure 2D). It is therefore possible that ligandtants in the fly eyes (Figure 1B), nuclear translocation
binding results in a conformational change of the hAR,of the polyQ-expanded hAR mutants was unlikely to be
making it more accessible to proteolysis, which allowsinhibited, as antagonist-induced nuclear translocation
for the generation of a potentially toxic polyQ-containingof hAR has been previously reported (Tomura et al.,
fragment.2001). These findings of the nuclear events are further
supported by the recent report that neurodegeneration
induced by polyQ repeats in huntingtin in the adult fly
A Clue to Rescue SBMA/Kennedy Diseaseeyes required a transcriptional cofactor, CBP (Steffan
All together, these findings suggest that nuclear localiza-et al., 2001).
tion with the ligand-dependent structural alteration is
critical for the onset of neurodegeneration by hAR. Al-Ligand Binding Causes Structural Alteration
though cellular formation of aggregates by polyQ-of hAR Mutants to Expose
expanded hAR mutants in cultured cells (Stenoien et al.,the PolyQ-Expanded A/B Domain
1999; Simeoni et al., 2000) and subsequent inhibitionLigand binding to nuclear receptors induces structural
of aggregate formation in the cytosol by antagonistsalterations, dissociation of corepressor complexes, and
(Becker et al., 2000) have been previously reported, itassociation of coactivator complexes for ligand-depen-
appears likely that the nuclear events caused by thedent transactivation (Freedman, 1999; Glass and Rosen-
polyQ-expanded hAR mutants are required for SBMAfeld, 2000; Mckenna and O’Malley, 2002; and Yanagi-
pathogenesis. If the mutated receptors could be trappedsawa et al., 2002). Crystallographic analyses of the
in the cytosol by a novel ligand, the toxicity of mutantstructural changes in LBDs of many nuclear receptors,
hAR might be prevented or at least reduced. For thisincluding AR, revealed that H12 is drastically shifted,
reason, androgen antagonists that still permit nuclearwhile other helices are also repositioned upon ligand
localization would not be useful therapeutically for thebinding (Poujol et al., 2000). The angle of H12 movement
treatment of SBMA. Thus, the hAR(Q52) Drosophila lineis ligand-type dependent and determines the agonistic/
is a useful SBMA model for drug development and forantagonistic action of the ligand. Improper H12 shifting
genetic screening for factors involved in androgen-and impaired pocket formation of the other helices by
induced neurodegeneration. In conclusion, we proposeantagonist binding may result in the lack of recruitment
that SBMA may be treated by giving patients novel hARof coactivator complexes to the ligand-bound LBD
(Shiau et al., 1998). These findings suggest a general ligands that prevent nuclear translocaton of hAR.
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